Please ensure Javascript is enabled for purposes of website accessibility

Abbott Labs to Sell 20.5 Million COVID-19 Antigen Tests to Canadian Government

By Eric Volkman – Oct 6, 2020 at 5:39PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The rapid-response, point-of-care tests should trim the long lines seen at some of the country's testing sites.

Abbott Laboratories (ABT 0.92%) has signed a deal with the government of Canada to potentially supply around 21 million of its Panbio COVID-19 tests, the latter announced on Tuesday. The move closely follows the approval of the test by Health Canada, the nation's healthcare industry regulator.

Panbio is an antigen test that can produce results on the spot in 20 minutes. It is also portable, making it ideal for testing in point-of-care sites outside of standard medical facilities.

This should alleviate the overcrowding seen at official testing centers in certain parts of the country. Some areas -- for instance, the province of Ontario, home to Ottawa, the capital -- are also struggling with a backlog of tens of thousands of samples from other tests that have yet to be evaluated. 

A coronavirus cluster.

Image source: Getty Images.

"To be clear, the strategy in terms of our procurements is not to replace the standardized testing model but to enhance the capacity of provinces and territories to keep up with the increasing demand for tests," Public Services and Procurement Minister Anita Anand was quoted as saying by the Canadian Broadcasting Company.

"Our strategy is one of diversification across various testing types and models," she added.

The government plans to distribute 8.5 million tests throughout the country by the end of this year. If those tests prove to be effective, Canada will exercise an option it holds with Abbott to obtain an additional 12.5 million.

No financial details of the arrangement have yet been made public.

Abbott's shares dipped by 2.1% on Tuesday, a steeper fall than that suffered by the S&P 500 index.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
$104.81 (0.92%) $0.95

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.